At these lower doses, systemically administered immunotherapies, be they ICIs, bispecific antibodies, or immune-stimulating cytokines, such as interleukin-2 (IL-2) or interferon-alpha (IFN-α), are unlikely to reach optimal concentrations within a tumor [3]. The gene discussed is IL2; the disease is neoplasm.